HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Touré, F. S. Articles by Migot-Nabias, F. Search for Related Content PubMed PubMed Citation Articles by Touré, F. S. Articles by Migot-Nabias, F.

Analysis of Human Antibodies to Erythrocyte Binding Antigen 175 Peptide 4 of Plasmodium falciparum

Fousseyni S. Touré, PhD, Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon.
Philippe Deloron, MD, PhD, Centre International de Recherches Médicales de Franceville, BP 769 Franceville, Gabon and UR 010, Institut de Recherche pour le Développement (IRD), Paris, France.
Florence Migot-Nabias, PhD, UR 010, Institut de Recherche pour le Développement (IRD), Cotonou, Bénin.

Reprint Requests: Fousseyni S. Touré, PhD, Centre International de Recherches, Médicales de Franceville, BP 769 Franceville, Gabon, Tel: 00 241 06615636; Fax: 00 241 677095; E-mail: fousseyni{at}yahoo.fr

Background: The IgG1 and IgG3 antibodies are considered cytophilic and protective against Plasmodium falciparum, whereas IgG2 and IgG4 are thought to block protective mechanisms.

Objectives: The main objective was to measure antibodies directed against erythrocyte binding antigen-175 (EBA-175) peptide 4 and analyze the relationship between such antibodies and clinical malaria attack.

Methods: Using an enzyme-linked immunosorbent assay, a retrospective analysis of naturally acquired antibodies to synthetic peptide from EBA-175 peptide 4 has been carried out in 158 school children from the village of Dienga in Gabon.

Results: The overall prevalence rates of antibodies to EBA-175 peptide 4 were 85.2%, 66.8%, 52.6%, 71.6% and 64.0% for total IgG, IgG1, IgG2, IgG3 and IgG4, respectively. Protection from clinical malaria, determined after a prospective 1-year study, was associated with the levels of IgG and IgG1 antibodies that increased with age.

Conclusion: Together, these data suggest that age/exposure-related acquisition of anti-EBA-175 antibodies may contribute to the development of clinically protective immunity and could be taken into account in malaria control strategies when they are confirmed.

Key Words: Clinical malaria • EBA-175 peptide 4 • Immune response • Plasmodium falciparum

This article has been cited by other articles:

				F. H. A. Osier, G. Fegan, S. D. Polley, L. Murungi, F. Verra, K. K. A. Tetteh, B. Lowe, T. Mwangi, P. C. Bull, A. W. Thomas, et al. Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria Infect. Immun., May 1, 2008; 76(5): 2240 - 2248. [Abstract] [Full Text] [PDF]

				L. Ford, C. A. Lobo, M. Rodriguez, M. G. Zalis, R. L. D. Machado, A. R. B. Rossit, C. E. Cavasini, A. A. R. Couto, P. A. Enyong, and S. Lustigman Differential Antibody Responses to Plasmodium falciparum Invasion Ligand Proteins in Individuals Living in Malaria-Endemic Areas in Brazil and Cameroon Am J Trop Med Hyg, November 1, 2007; 77(5): 977 - 983. [Abstract] [Full Text] [PDF]